Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

← catalyst calendar

NCT05683977 · readout in 194 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Kappa Santé.

Phase
Status
Active, not recruiting
Study type
Observational
Enrollment
254actual
Sites
34
Country
France

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-11-14actualWhen the study began enrolling
Primary completion2027-03-01estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-03-01estimatedThe whole study's end, after follow-up
First posted2023-01-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Small Cell Lung Carcinoma

Intervention

  • Drug: durvalumab

Primary outcome

what the primary-completion date above is the date OF
The time to first line treatment discontinuation (TTD).
measured TTD is defined as the time from the index date to the date of last durvalumab infusion (+3 weeks during induction period and +4 weeks during maintenance period) or date of death (up to 36 months)).

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed